

Medicinal Product	Marketing Authorisation Holder	Therapeutic Indication	Date of Marketing Authorisation
Alofisel® (darvadstrocel)	Tigenix, S.A.U.	Complex anal fistulas in adults with Crohn's disease	23/03/2018
Amglidia® (glibenclamide)	Ammtrek	Neonatal diabetes	24/05/2018
Crysvita® (burosumab)	Kyowa Kirin Limited	X-linked hypophosphataemia	19/02/2018
Jorveza® (budesonide)	Dr. Falk Pharma GmbH	Eosinophilic oesophagitis	08/01/2018
Lamzede® (velmanase alfa)	Chiesi Farmaceutici S.p.A.	Alpha-mannosidosis	23/03/2018
Mylotarg® (gemtuzumab ozogamicin)	Pfizer Limited	Acute myeloid leukemia	19/04/2018
Premyvis® (letermovir)	Merck Sharp & Dohme Limited	Cytomegalovirus infection prevention following haematopoietic stem cell transplant	08/01/2018
Rubraca® (rucaparib)	Clovis Oncology UK Limited	High-grade cancers of the ovary, fallopian tubes and peritoneum	24/05/2018